Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.

Cancer science - 1 Sept 2016

Suzuki Yasuhiro, Tomita Akihiro, Nakamura Fumika, Iriyama Chisako, Shirahata-Adachi Mizuho, Shimada Kazuyuki, Akashi Akimi, Ishikawa Yuichi, Kaneda Norio, Kiyoi Hitoshi

Abstract excerpt

Genetic alterations in myelodysplastic syndromes (MDS) are critical for pathogenesis. We previously showed that peripheral blood cell-free DNA (PBcfDNA) may be more sensitive for genetic/epigenetic analyses than whole bone marrow (BM) cells and mononuclear cells in peripheral blood (PB). Here we analyzed the detailed features of PBcfDNA and its utility in genetic analyses in MDS. The plasma-PBcfDNA concentration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Blood Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow Cells

Share to Cell Transformation, Neoplastic

Share to Disease Progression

Share to DNA, Neoplasm

Share to Early Detection of Cancer

Share to Myelodysplastic Syndromes

Source

Open in PubMed Open full text

Identifiers

PMID: 27323954
DOI: 10.1111/cas.12994
PMCID: PMC5021037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.PMID 27323954Read ↗

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.Semantic proximity Read ↗

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.Semantic proximity Read ↗

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA.Semantic proximity Read ↗

Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis.Semantic proximity Read ↗

Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndromeSemantic proximity Read ↗

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemiaSemantic proximity Read ↗

Prognostic impact of circulating tumor DNA status post–allogeneic hematopoietic stem cell transplantation in AML and MDSSemantic proximity Read ↗

Plasma cell-free DNA in patients with acute promyelocytic leukemia treated with arsenic trioxideSemantic proximity Read ↗

Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemiaSemantic proximity Read ↗

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasiaSemantic proximity Read ↗

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.